Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease

Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease

BackgroundRegistration authorities evaluate effects of new medicines for chronic obstructive pulmonary disease (COPD) on airway obstruction, dyspnea, health status and exacerbations. To establish clinical relevance, minimal clinically important differences (MCIDs) are used. The aim of this study was...

Cijeli opis

Bibliografski detalji
Glavni autori: Marloes Dankers, Marjorie H. J. M. G. Nelissen-Vrancken, Sara M. K. Surminski, Anke C. Lambooij, Tjard R. Schermer, Liset van Dijk
Format: Članak
Jezik:English
Izdano: Frontiers Media S.A. 2020-02-01
Serija:Frontiers in Pharmacology
Teme:
clinical relevance
minimal clinically important differences
patient-reported outcomes
chronic obstructive pulmonary disease
new medicine
forced expiratory volume in 1 sec
Online pristup:https://www.frontiersin.org/article/10.3389/fphar.2019.01519/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.01519/full

Slični predmeti